Clinical Trial Update: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) [Phase 1, Phase 2]

View source ↗

Summary

This document is a completed Phase 1/Phase 2 clinical trial update for CAB-ROR2-ADC evaluating safety and efficacy in non-small cell lung cancer, triple-negativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CAB-ROR2-ADC

Snippet

Sponsor: BioAtla, Inc. | Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED